Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Pardi

Showing results (91-100 of 145) with videos related to

Pageof 15
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 4, 2020
A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in MiceAlec W Freyn, Jamile Ramos da Silva, Victoria C Rosado, et al.
Nature Communications|March 3, 2017
Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challengeNorbert Pardi, Anthony J Secreto, Xiaochuan Shan, et al.
Science Advances|December 14, 2022
A universal influenza mRNA vaccine candidate boosts T cell responses and reduces zoonotic influenza virus disease in ferretsKoen van de Ven, Josien Lanfermeijer, Harry van Dijken, et al.
Frontiers in Immunology|December 1, 2022
A minimally-edited mouse model for infection with multiple SARS-CoV-2 strainsSandra Nakandakari-Higa, Roham Parsa, Bernardo S Reis, et al.
Nature Communications|June 9, 2021
Nucleoside-modified VEGFC mRNA induces organ-specific lymphatic growth and reverses experimental lymphedemaDániel Szőke, Gábor Kovács, Éva Kemecsei, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 2, 2022
Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza virusesMeagan McMahon, George O'Dell, Jessica Tan, et al.
Nature Communications|January 16, 2026
Optimal murine CD4<sup>+</sup> T cell priming by mRNA-lipid nanoparticle vaccines requires endogenous antigen processingJulia E Rood, Suh Kyung Yoon, Mary K Heard, et al.
Biorxiv : the Preprint Server for Biology|July 9, 2024
Transient inhibition of type I interferon enhances CD8 <sup>+</sup> T cell stemness and vaccine protectionBenjamin J Broomfield, Chin Wee Tan, Raymond Z Qin, et al.
Biorxiv : the Preprint Server for Biology|March 24, 2021
Chimeric spike mRNA vaccines protect against Sarbecoviru<i>s</i> challenge in miceDavid R Martinez, Alexandra Schäfer, Sarah R Leist, et al.
Science (New York, N.Y.)|July 2, 2021
Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in miceDavid R Martinez, Alexandra Schäfer, Sarah R Leist, et al.
Pageof 15

Showing results (91-100 of 145) with videos related to

Sort By:
Pageof 15
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 4, 2020
A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in MiceAlec W Freyn, Jamile Ramos da Silva, Victoria C Rosado, et al.
Nature Communications|March 3, 2017
Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challengeNorbert Pardi, Anthony J Secreto, Xiaochuan Shan, et al.
Science Advances|December 14, 2022
A universal influenza mRNA vaccine candidate boosts T cell responses and reduces zoonotic influenza virus disease in ferretsKoen van de Ven, Josien Lanfermeijer, Harry van Dijken, et al.
Frontiers in Immunology|December 1, 2022
A minimally-edited mouse model for infection with multiple SARS-CoV-2 strainsSandra Nakandakari-Higa, Roham Parsa, Bernardo S Reis, et al.
Nature Communications|June 9, 2021
Nucleoside-modified VEGFC mRNA induces organ-specific lymphatic growth and reverses experimental lymphedemaDániel Szőke, Gábor Kovács, Éva Kemecsei, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 2, 2022
Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza virusesMeagan McMahon, George O'Dell, Jessica Tan, et al.
Nature Communications|January 16, 2026
Optimal murine CD4<sup>+</sup> T cell priming by mRNA-lipid nanoparticle vaccines requires endogenous antigen processingJulia E Rood, Suh Kyung Yoon, Mary K Heard, et al.
Biorxiv : the Preprint Server for Biology|July 9, 2024
Transient inhibition of type I interferon enhances CD8 <sup>+</sup> T cell stemness and vaccine protectionBenjamin J Broomfield, Chin Wee Tan, Raymond Z Qin, et al.
Biorxiv : the Preprint Server for Biology|March 24, 2021
Chimeric spike mRNA vaccines protect against Sarbecoviru<i>s</i> challenge in miceDavid R Martinez, Alexandra Schäfer, Sarah R Leist, et al.
Science (New York, N.Y.)|July 2, 2021
Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in miceDavid R Martinez, Alexandra Schäfer, Sarah R Leist, et al.
Pageof 15